低剂量阿糖胞苷联合或不联合格拉吉布治疗新诊断急性髓系白血病或高危骨髓增生异常综合征患者的随机对照研究
这项II期随机开放标签多中心研究纳入不适合强化化疗的急性髓系白血病或高危骨髓增生异常综合征患者,按2:1随机接受格拉吉布联合低剂量阿糖胞苷或单用低剂量阿糖胞苷。联合组中位总生存期为8.8个月,单药组为4.9个月(HR 0.51,80%CI 0.39-0.67,P=0.0004)。格拉吉布联合低剂量阿糖胞苷具有有利的风险获益特征,可能是不适合强化化疗的AML患者的有前景选择。
要点
- 格拉吉布联合低剂量阿糖胞苷较单用低剂量阿糖胞苷延长了中位总生存期(8.8 vs 4.9个月)。
- 联合组完全缓解率为17.0%,单药组为2.3%(P<0.05)。
- 联合组非血液学3/4级不良事件包括肺炎(16.7%)和乏力(14.3%)。
核心结论
- 格拉吉布联合低剂量阿糖胞苷具有有利的风险获益特征,可能是不适合强化化疗的AML患者的有前景选择。
研究设计与样本
- II期随机开放标签多中心研究(ClinicalTrials.gov,NCT01546038),纳入不适合强化化疗的新诊断急性髓系白血病或高危骨髓增生异常综合征患者,按细胞遗传学风险分层后以2:1随机接受格拉吉布联合低剂量阿糖胞苷或单用低剂量阿糖胞苷。
主要发现
- 格拉吉布联合低剂量阿糖胞苷组88例,单用低剂量阿糖胞苷组44例。
- 中位总生存期(80%置信区间[CI])联合组为8.8(6.9-9.9)个月,单药组为4.9(3.5-6.0)个月(风险比0.51;80%CI 0.39-0.67,P=0.0004)。
- 联合组15例(17.0%)和单药组1例(2.3%)达到完全缓解(P<0.05)。
- 联合组非血液学3/4级全因不良事件包括肺炎(16.7%)和乏力(14.3%),单药组包括肺炎(14.6%)。
- 临床疗效在不同突变谱的患者中均可见。
关键数值与推荐
- 格拉吉布100 mg口服每日一次,连续给药,28天为一周期;低剂量阿糖胞苷20 mg皮下注射每日两次,每28天给药10天。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glasdegib is a Hedgehog pathway inhibitor. This phase II, randomized, open-label, multicenter study (ClinicalTrials.gov, NCT01546038) evaluated the efficacy of glasdegib plus low-dose cytarabine (LDAC) in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome unsuitable for intensive chemotherapy. Glasdegib 100 mg (oral, QD) was administered continuously in 28-day cycles; LDAC 20 mg (subcutaneous, BID) was administered for 10 per 28 days. Patients (stratified by cytogenetic risk) were randomized (2:1) to receive glasdegib/LDAC or LDAC. The primary endpoint was overall survival. Eighty-eight and 44 patients were randomized to glasdegib/LDAC and LDAC, respectively. Median (80% confidence interval [CI]) overall survival was 8.8 (6.9-9.9) months with glasdegib/LDAC and 4.9 (3.5-6.0) months with LDAC (hazard ratio, 0.51; 80% CI, 0.39-0.67, P = 0.0004). Fifteen (17.0%) and 1 (2.3%) patients in the glasdegib/LDAC and LDAC arms, respectively, achieved complete remission (P < 0.05). Nonhematologic grade 3/4 all-causality adverse events included pneumonia (16.7%) and fatigue (14.3%) with glasdegib/LDAC and pneumonia (14.6%) with LDAC. Clinical efficacy was evident across patients with diverse mutational profiles. Glasdegib plus LDAC has a favorable benefit-risk profile and may be a promising option for AML patients unsuitable for intensive chemotherapy.
引用
- Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2018. PMID: 30555165. doi:10.1038/s41375-018-0312-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。